Liquidia Plunges 25% as Court Denies Motion to Strike in Yutrepia Patent Fight
LQDA has more than doubled off its 52-week low of $21.35 on elevated volume (1.9× avg).
Summary
Liquidia shares fell 25% after Judge Richard G. Andrews denied the company's motion to strike in its patent dispute with United Therapeutics over Yutrepia. The ruling is a setback for Liquidia's defense against United Therapeutics' infringement claims, which threaten the drug's market presence. United Therapeutics rose 6.2% on the news. This follows a period of heavy insider selling at Liquidia and ongoing litigation risk disclosed in its Q2 10-Q. The next key event will be the court's substantive ruling on the patent dispute.
At the time of this announcement, LQDA was trading at $53.22 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.8B. The 52-week trading range was $21.35 to $93.61. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Seeking Alpha.